1. Opening Remarks Trioday, a product of Cipla Ltd., falls under the category of fixed-dose combination (FDC) antiretrovirals. It is prescribed for individuals infected with HIV. The convenience of a single-tablet, once-daily regimen has made it a valuable tool in modern HIV care, merging three separate drugs into one oral dose. The arrival of

1. Introduction and Overview Cipla Ltd.'s Trioday is a fixed-dose combination (FDC) antiretroviral medication designed for the treatment of HIV infection. As a once-daily single-tablet regimen, it simplifies HIV management by combining three active drugs into one convenient dose. Fixed-dose combinations like Trioday have transformed HIV care by